Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $4.8000 (3%) ($4.8000 - $4.8000) on Tue. Jan. 11, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.01% (three month average) | RSI | 38 | Latest Price | $4.8000(3%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.7% a day on average for past five trading days. | Weekly Trend | AUTL declines -5.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(66%) IBB(60%) IBUY(58%) ARKG(56%) ARKK(54%) | Factors Impacting AUTL price | AUTL will decline at least -2.505% in a week (0% probabilities). VIXM(-42%) VXX(-34%) TLT(-24%) SHY(-22%) TIP(-20%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.505% (StdDev 5.01%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-5.98(-224.58%) | Resistance Level | $5.21 | 5 Day Moving Average | $4.77(0.63%) | 10 Day Moving Average | $5(-4%) | 20 Day Moving Average | $5.21(-7.87%) | To recent high | -31.9% | To recent low | 3.3% | Market Cap | $251m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |